美多芭联合恩他卡朋对中晚期帕金森患者的临床疗效研究

目的:对美多芭联合恩他卡朋治疗中晚期帕金森患者的临床疗效进行观察和总结.方法:65例临床确诊为原发性帕金森病的患者,随机分为美多芭组32例,单独给予美多芭治疗,联合组33例,在美多芭组用药的基础上联用恩他卡朋治疗.两组患者均治疗12周.对比治疗前后外周血中LD的血药浓度、UPDRS评分及血浆SOD、MDA、GSH、GSH-PX水平.结果:对比美多芭组,联合组治疗后能提高LD的血药浓度,降低UPDRS评分,抗氧化能力有所改善,差异有统计学意义(P<0.05);美多芭组治疗后血药浓度较治疗前有所下降,但差异无统计学意义.结论:联合用药能提高中晚期PD患者外周血中的LD血药浓度,改善症状,提高机体抗氧化水平.

Clinical Curative Effect of Madopar Combining Entacapone in Patients with Middle-late Parkinson's Patients

Objective: To observe and summarize the clinical curative effect of madopar combining en-tacapone in middle-late Parkinson's disease (PD) patients. Methods: Sixty-five cases of clinically diagnosed idiopathic Parkinson's disease were randomly divided, 32 subjects were treated with madopar (madopar group) and 33 subjects were treated with madopar combining entacapone (combination group). The two groups of patients were treated for 12 weeks. Before and after treatment, levodopa (LD) concentration in peripheral blood, UPDRS scores and levels of SOD, MDA, GSH and GSH-PX in peripheral blood were recorded and compared. Results: Compared with the madopar group, the combination group showed higher blood LD concentrations and antioxidant capacity, lower UPDRS scores, the differences were statistically significant (P<0.05). Conclusion: Madopar combining entacapone can improve clinical symptoms and raise blood LD concentrations and antioxidant levels in middle-late Parkinson's patients.